SLC5A2 and type 2 diabetes mellitus: <b>Conclusion:</b> Results from RCTs confirmed lower risk of death, serious adverse events, hypertension, and edema associated with type 2 diabetes mellitus (T2DM) patients treated with SGLT2 inhibitors when compared with placebo.